# PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

> **NCT01621490** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 170 (actual)

## Conditions studied

- Advanced Melanoma
- Metastatic Melanoma

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT01621490
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09-27
- **Primary completion:** 2017-09-12
- **Final completion:** 2018-10-25
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2024-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01621490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01621490, "PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01621490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*